Blood filtration for severe ulcerative colitis or Crohn's disease
Part of Digestive system clinical trials.
This trial tests a blood-cleaning treatment called Efferon LPS that removes harmful toxins from your blood. It's for people with ulcerative colitis or Crohn's disease whose symptoms are not getting better with usual treatments, and it might help reduce inflammation and calm your flare.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a diagnosis of moderate to severe ulcerative colitis or Crohn's disease that is currently flaring.
- Your flare must be severe, or moderate and not responding to steroids (or you can't stop steroids without symptoms returning).
- You've had symptoms for at least 3 months before joining.
- Your doctor must have confirmed the diagnosis with a scope (endoscopy) and biopsy.
- You haven't had recent bowel surgery (like removing part of the colon or creating a stoma) in the last 6 months.
- You don't have other serious conditions like active infections, cancer in the last 5 years, recent heart attack, stroke, or kidney failure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding hyperbaric oxygen therapy—breathing pure oxygen in a pressurized chamber—to standard care can help people with a severe flare of ulcerative colitis (a type of inflammatory bowel disease). It may reduce inflammation and speed up recovery.
This trial tests whether a stool transplant (fecal microbiota transplantation) can help manage active ulcerative colitis. You would receive a transplant from a healthy donor to see if it improves your symptoms.
This study checks biomarkers (signals in blood and/or stool) in adults with moderate-to-severe ulcerative colitis. It compares patients starting targeted medicines and looks for marker patterns that may reflect how the disease is behaving.
This trial tests whether fecal microbiota transfer (a stool-based therapy) can improve outcomes when added to starting a new biologic medicine for ulcerative colitis. It compares fecal transplant versus placebo (a sham treatment) to see if symptoms and inflammation improve faster or more strongly.
This trial tests whether fecal microbiota transplantation (FMT) can safely and effectively treat mild to moderate ulcerative colitis over the long term. FMT involves transferring stool from a healthy donor to restore a healthy balance of gut bacteria.
This trial tests if a fecal transplant combined with dietary changes can help control symptoms in people with active ulcerative colitis who haven't responded well to standard treatments or advanced therapies.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.